Similar articles

• Management of otitis media in the era of managed care.

  Klein JO, Bluestone CD. Klein JO, et al. Adv Pediatr Infect Dis. 1996;12:351-86. Adv Pediatr Infect Dis. 1996. PMID: 9033984 Review. No abstract available.
• Incidence and antimicrobial resistance of pathogenic bacteria isolated from children with acute otitis media in Athens, Greece, during the periods 2003-2004 and 2005-2007.

  Papavasileiou K, Papavasileiou E, Voyatzi A, Makri A, Chatzipanagiotou S. Papavasileiou K, et al. Int J Antimicrob Agents. 2009 Feb;33(2):183-4. doi: 10.1016/j.ijantimicag.2008.07.024. Epub 2008 Oct 9. Int J Antimicrob Agents. 2009. PMID: 18848435 No abstract available.
• Correlation between bacteriologic and clinical endpoints in trials of acute otitis media.

  Johann-Liang R, Zalkikar J, Powers JH. Johann-Liang R, et al. Pediatr Infect Dis J. 2003 Oct;22(10):936-7; author reply 937. doi: 10.1097/01.inf.0000092637.66762.c6. Pediatr Infect Dis J. 2003. PMID: 14551499 No abstract available.
• Controversies in the management of pediatric otitis media. Are more definitive answers on the horizon?

  Carlson L, Scudder L. Carlson L, et al. Adv Nurse Pract. 2004 Feb;12(2):73-7. Adv Nurse Pract. 2004. PMID: 14986495 Review. No abstract available.
• An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media.

  Arguedas A, Dagan R, Pichichero M, Leibovitz E, Blumer J, McNeeley DF, Melkote R, Noel GJ. Arguedas A, et al. Pediatr Infect Dis J. 2006 Dec;25(12):1102-9. doi: 10.1097/01.inf.0000246828.13834.f9. Pediatr Infect Dis J. 2006. PMID: 17133154 Clinical Trial.